BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay ...Middle East

(Bloomberg) — The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns. MediLink stopped enrolling US patients in the study, which had aimed to recruit 80 volunteers to test a new antibody-drug conjugate, a type of medicine designed to deliver targeted therapy to a tumor, BioNTech said Monday. Run in China and the US, the study had been scheduled to deliver results at the end of this year, according to a US government registry of clinical trials.  The FDA told MediLink that it was concerned that the compound “may, at higher doses, expose hum

Hence then, the article about biontech cancer drug licensed from medilink faces fda delay was published today ( Monday 17/06/2024 - 10:37 PM ) and is available on NY Times News ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay )

Also on site :

• North Korean operatives stole $2 billion last year—and financial firms are the next target
• Nepal in a bind as US-China drone war reaches Everest
• Polestar CEO tells CNBC ‘pump anxiety’ has made EVs ‘all about money’